Safety Issues Clinical Trial
Official title:
SENSAMED. Medication Errors in the Spanish System of Communication of Incidents in Anaesthesia: Ten Year Analysis.
Background: The incidents related to medication are an important cause of avoidable health
damage in the perioperative environment.
Objectives: Describe the incidents related to medication reported in the national
communication system of incidents in anaesthesia and resuscitation in Spain (SENSAR), and
their relationship with morbidity.
Methods: The investigators studied the incidents identified as medication errors of all those
reported in the SENSAR database between January 1, 2008 and December 31, 2017. The
researchers performed a descriptive analysis of independent variables: type of medication
incident, moment in which the incident occurred, drug group involved and then a logistic
regression in order to establish the relationship with the dependent variable: morbidity.
DESIGN AND APPROVAL This observational study was conducted between January 1, 2008, and
December 31, 2017, after approval from the institutional review board (Ethics Committee of
the La Fe University and Polytechnic Hospital (number) Valencia, using data from the Spanish
Anaesthesia and Reanimation Incident Reporting System (SENSAR) to retrieve the medication
related patient safety incidents. The methodology followed the recommendations of the
Strengthening the Reporting of Observational studies in Epidemiology (STROBE) statement. The
Standards for Quality Improvement Reporting Excellence (SQUIRE) were used to write the
manuscript.
FRAMEWORK (study setting) All the data analysed in this study was obtained from SENSAR, which
is a national, multi centre incident notification system focusing on the perioperative
environment. Until December 2017, it included 104 hospitals in Spain and Chile. The
incorporation of hospitals into the network was gradual and progressive since its inception
in 2008. Voluntarily, anonymously and on a non-punitive basis, anaesthesiologists, resident
doctors in training and anaesthesia and resuscitation nurses can communicate any security
incident using a web form accessed with a generic key for each assigned centre, ensuring the
anonymity of the communicator. In this database, the communication is recorded in a
structured form together with a free text for the detailed description of the incident. In
each hospital there is a group of professionals in charge of the anonymous and confidential
analysis of the incidents based on the London Protocol (*+*), which proposes measures to
avoid the repetition of incidents and gives feedback to the notifiers.
The investigators define patient safety incident as any event or circumstance in which there
could be, or has been, unnecessary harm caused to a patient (*).
During the analysis process, the incidents reported are classified according to the type of
incident through a classification adapted to the perioperative environment. Adverse Events
that are not preventable are also included in the researchers classification (annex).
STUDY POPULATION (Subjects) (Data collection) (Observers) The study population consisted of
communications and analysis of the SENSAR database between January 1, 2008 and December 31,
2017. The investigators selected incidents classified as medication incidents from the
structured information included in the database at the time of notification and subsequent
analysis of the incident. In incidents for which there was no classification of type of
incident, two authors (ER and YS) individually reviewed each case with the reading of the
free texts of the form in search of incidents related to medication. The discrepancies
between the two observers were resolved by a third author (DA).
STUDY VARIABLES For the descriptive analysis of the incidents, the investigators used the
following categorical variables: type of medication incident, moment in which the incident
occurred, drug group involved, and morbidity generated. Regarding the independent variables,
the type of medication incident was classified by omission of the administration of the drug,
the administration of expired products, the mistake in the selection of drug, recommendation,
concentration or points of administration; the moment in which the incident occurred in the
prescription, preparation, dispensing, administration or monitoring of the drug, following
SENSAR's own classification, adapted to the perioperative environment. For the analysis of
the drugs involved, the investigators used their own classification (Table 1).
For the dependent variable, morbidity caused by the incident, the researchers used the WHO
taxonomy that orders the morbidity degrees in the following categories: no harm, minor
morbidity, intermediate morbidity, major morbidity and death (*).
STATISTICAL METHODS. The researchers use the statistical software, "R", version 3.4.1, to
perform the analysis of the sample obtaining, in absolute numbers and percentages, the
frequency with which the different types of reported incidents have occurred. To determine
the existence of a population-level relationship between the different independent variables
used and the damage produced in the patient, the researchers used the Kruskal-Wallis
non-parametric test with a level of significance of 5%. The result of this test will be
expressed with the obtained contrast statistic and its p-value. To identify the factors that
best estimate the risk of producing different degrees of morbidity in the patient, the
investigators generated a multiple ordinal logistic regression model. The effects presented
in this case will be the estimator, the standard error, the "odds ratio", the confidence
intervals at 95% and the p-value for a significance of 5%.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04485481 -
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT03473236 -
Phase 1A Safety Trial of Inhaled PK10571 (GB002)
|
Phase 1 | |
Not yet recruiting |
NCT03683953 -
The Treatment of Bronchopulmonary Dysplasia by Intratracheal Instillation of Mesenchymal Stem Cells
|
Phase 1 | |
Recruiting |
NCT05546567 -
NOPARK Open Label Extension Study
|
N/A | |
Recruiting |
NCT05413226 -
Effect of Different Ingestion Doses of Celastrol on Human Sperm Motility
|
N/A | |
Recruiting |
NCT05112159 -
Study of IPG1094 in Healthy Participants
|
Phase 1 | |
Completed |
NCT04689035 -
A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability and Pharmacokinetics of AVLX-144
|
Phase 1 | |
Completed |
NCT04335045 -
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
|
Phase 1 | |
Completed |
NCT05037227 -
Safety Profile Following Inactivated COVID-19 Vaccine in Healthy Adults Aged >18 Years in Indonesia
|
||
Recruiting |
NCT05517291 -
DCB Versus Primary Selective Stenting in TASC C/D Femoropopliteal Artery Disease
|
N/A | |
Enrolling by invitation |
NCT06446778 -
Haemodynamic Mechanisms and Multicentre Prospective Cohort Study of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms. Evaluation of the Safety and Efficacy of the Pipeline Flow-diverting Device for the Treatment of Intracranial Aneurysms
|
||
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Completed |
NCT04188821 -
Reduction of Seroma and Improvement of QoL in Breast Reconstruction With Tissue Expander
|
N/A | |
Completed |
NCT03667430 -
Safety Evaluation of Porous Silica in Men
|
N/A | |
Completed |
NCT04499482 -
Safety and Tolerability of Soy Fiber
|
N/A | |
Completed |
NCT03141905 -
Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05244161 -
A Quasi-experimental Evaluation of the Malezi Program in Tanzania
|
N/A | |
Recruiting |
NCT03791372 -
Clinical Effect and Safety of Autologous Umbilical Cord Blood Transfusion in the Treatment of Cerebral Palsy
|
Phase 1 | |
Withdrawn |
NCT04759066 -
The HEALiX™ Intubated Patient (IP) Pilot Study
|
N/A |